Brief: Sana Biotechnology Announces Positive Clinical Results From Type 1 Diabetes Study Of Islet Cell Transplantation Without Immunosuppression
07/01/2025 22:44
Jan 7 (Reuters) - Sana Biotechnology Inc SANA.O :
* SANA BIOTECHNOLOGY ANNOUNCES POSITIVE CLINICAL RESULTS
FROM TYPE
1 DIABETES STUDY OF ISLET CELL TRANSPLANTATION WITHOUT
IMMUNOSUPPRESSION
* SANA BIOTECHNOLOGY INC - STUDY IDENTIFIES NO SAFETY
ISSUES,
HIP-MODIFIED ISLET CELLS EVADE IMMUNE RESPONSES
* SANA BIOTECHNOLOGY INC -MRI SHOWS SIGNALS CONSISTENT WITH
GRAFT
SURVIVAL 28 DAYS AFTER TRANSPLANTATION
Source text: ID:nGNX996qx5
Further company coverage: SANA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sana Biotechnology
See all newsSana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Brief: Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Brief: Sana Biotechnology Q1 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.17